ENTA Stock Overview
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.83 |
52 Week High | US$23.98 |
52 Week Low | US$8.08 |
Beta | 0.57 |
11 Month Change | -5.13% |
3 Month Change | -19.14% |
1 Year Change | -48.36% |
33 Year Change | -75.26% |
5 Year Change | -85.45% |
Change since IPO | -31.14% |
Recent News & Updates
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Recent updates
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Shareholder Returns
ENTA | US Biotechs | US Market | |
---|---|---|---|
7D | -11.1% | -2.2% | 0.7% |
1Y | -48.4% | 6.7% | 23.3% |
Return vs Industry: ENTA underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: ENTA underperformed the US Market which returned 22.3% over the past year.
Price Volatility
ENTA volatility | |
---|---|
ENTA Average Weekly Movement | 9.1% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ENTA's share price has been volatile over the past 3 months.
Volatility Over Time: ENTA's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 145 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
ENTA fundamental statistics | |
---|---|
Market cap | US$250.55m |
Earnings (TTM) | -US$131.74m |
Revenue (TTM) | US$72.88m |
3.4x
P/S Ratio-1.9x
P/E RatioIs ENTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENTA income statement (TTM) | |
---|---|
Revenue | US$72.88m |
Cost of Revenue | US$0 |
Gross Profit | US$72.88m |
Other Expenses | US$204.62m |
Earnings | -US$131.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 05, 2024
Earnings per share (EPS) | -6.22 |
Gross Margin | 100.00% |
Net Profit Margin | -180.75% |
Debt/Equity Ratio | 110.1% |
How did ENTA perform over the long term?
See historical performance and comparison